department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Verquvo · pharmadog

pharmadog
drugs
Verquvo

drug

patient view →

vericiguat

Marketedupdated 2mo ago

by Merck Sharp & Dohme LLC

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Verquvo

generic

vericiguat

indication

Systolic Heart Failure (HFrEF)

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Jan 21, 2029

~2.5 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (18)

Nov 26, 2032compositionUS 9604948
Nov 26, 2032compositionUS 9604948
Nov 26, 2032compositionUS 9604948
May 19, 2031compositionUS 107368964.9y
May 19, 2031compositionUS 107368964.9y
May 19, 2031compositionUS 107368964.9y
May 19, 2031method-of-use (U-3062)US 114396424.9y
May 19, 2031method-of-use (U-3062)US 114396424.9y
May 19, 2031method-of-use (U-3062)US 114396424.9y
May 19, 2031compositionUS 84206564.9y
May 19, 2031compositionUS 84206564.9y
May 19, 2031compositionUS 84206564.9y
May 19, 2031method-of-use (U-3062)US 89213774.9y
May 19, 2031method-of-use (U-3062)US 89213774.9y
May 19, 2031method-of-use (U-3062)US 89213774.9y
May 19, 2031method-of-use (U-3062)US 99934764.9y
May 19, 2031method-of-use (U-3062)US 99934764.9y
May 19, 2031method-of-use (U-3062)US 99934764.9y

FDA exclusivities (6)

Jan 21, 2029D-198New Indication (3y)2.5y
Jan 21, 2029D-198New Indication (3y)2.5y
Jan 21, 2029D-198New Indication (3y)2.5y
Jan 19, 2026NCENew Chemical Entity (5y)
Jan 19, 2026NCENew Chemical Entity (5y)
Jan 19, 2026NCENew Chemical Entity (5y)

Data sources

ClinicalTrials.gov

last refreshed 2h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 2

tagApproval16 co-mentions · 4 sources
tagSmall Molecule8 co-mentions · 4 sources

Trials studying vericiguat

—An Observational Study to Learn More About the Use of Vericiguat in Korean People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in Real-world Settingrecruitingn=1,350
phase3Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)recruitingn=342
—A Study to Learn More About the Safety of the Drug Vericiguat in Japanese People With Chronic Heart Failure Who Will be Receiving Vericiguat Under Real-world Conditionsrecruitingn=1,400
—An Observational Study to Learn More About How Safe Vericiguat is and How Well it Works in Indian People With Chronic Heart Failure With Reduced Ejection Fraction and Worsening Chronic Heart Failure Under Real World Conditionsactive not recruitingn=604
—An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in Chinacompletedn=2,400
phase2Study to Investigate Improvement in Physical Function in SF-36 With Vericiguat Compared With Placebo in Participants With Post-COVID-19 Syndromeactive not recruitingn=104
phase2Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunctioncompletedn=45
phase3A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)completedn=6,106

more trials →